Lifevantage Corporation: stock overview

LFVNNASDAQHealthcare · Pharmaceutical Preparations

Price

$4.97

November 13, 2026Market cap $62M

DCF calculator

What Ploutos Investor adds for Lifevantage

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Lifevantage had revenue of $172M over the last 12 months and net income of $2.7M, a net margin of 1.6%. Revenue fell by 3.7% a year on average over the last 5 years. At $4.97 the shares trade at a P/E of 22.9, against a median of 18.1 over the last 5 fiscal years. It holds more cash than debt, by $14M. It pays a dividend yielding 3.82%.

From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$62M
12.53M shares
P/E
22.9
Today22.9
Median18.1
Revenue, 12 months
$172M
-3.7% a year over 5 years
Net margin
1.6%
FY2025: 4.3%, above 65% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

-4.5% a year over 2 years

  • FY2026Jun 30, 202610-K
    Revenue$183M
  • FY2025Jun 30, 202510-K
    Revenue$229M
  • FY2024Jun 30, 202410-K
    Revenue$200M

Fiscal years in figures

LFVN's revenue, profit, cash flow and dividend with each year-end price, from FY2011 to FY2023, 13 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $80M
$62M
Enterprise value 
$49M
P/E 3-year median: 17.4
22.9
EV / EBIT 
13.1
EV / Revenue 
0.3
P/B 3-year median: 3.1
1.9
FCF yield 3-year median: 8.5%
14.0%
Earnings yield 3-year median: 5.7%
4.4%

Profitability

Gross margin 
76.5%
Operating margin 
2.2%
Net margin 3-year median: 2.8%
1.6%
ROIC 
8.3%
ROIC, 5-year average 
16.8%
ROE 
8.2%

Growth

Revenue, yearly change 
-20.1%
EPS, yearly change 
-46.7%
FCF, yearly change 
-36.5%
Revenue, average a year 
-3.7%
EPS, average a year 
-15.0%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$14M
Total debt 
$9.4M
Of which operating leases 
$9.4M
Net cash 
$14M
Net debt / EBITDA 
-2.1x
Interest cover 
–
Current ratio 
1.91

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 3.0%
3.82%
Buybacks 
3.28%
Total returned 
7.10%
Shares, yearly change 
-1.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

80.4%

Above 94% of the 141 companies in its industry, and 96% of all.

Operating margin

5.3%

Above 62% of the 285 companies in its industry, and 51% of all.

Net margin

4.3%

Above 65% of the 302 companies in its industry, and 50% of all.

ROE

29.7%

Above 88% of the 267 companies in its industry, and 91% of all.

ROA

16.0%

Above 89% of the 313 companies in its industry, and 95% of all.

Revenue growth

14.2%

Above 64% of the 292 companies in its industry, and 72% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Lifevantage Corp
CIK
849146
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
June 30, 2026
Reporting currency
USD
Shares
12.53M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Lifevantage's filings show?

These are Lifevantage's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LFVN

Didn't find what you were looking for?

Ask us
What is LFVN's market cap?

Lifevantage Corporation's market cap is $62M, at a price of $4.97 on November 13, 2026 and 12.53M shares.

What is LFVN's P/E?

LFVN's P/E is 22.9, on earnings per share of $0.21 over the last 12 months. The median over the last 5 fiscal years was 18.1.

How much revenue does LFVN have?

Lifevantage had revenue of $172M over the last 12 months. Over the last 5 years it changed by -3.7% a year on average.

Does LFVN pay a dividend?

Yes. Lifevantage paid $0.19 per share over the last 12 months, a yield of 3.82% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Lifevantage Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.